TILRAY BRANDS INC - TLRY STOCK NEWS

Aphria and Tilray are set to hold special meetings on April 14 and April 16, 2021, to approve their proposed business combination. Aphria has received necessary regulatory approvals and an interim order from the Ontario Superior Court for the arrangement. The combined entity will become the world's largest cannabis company, projecting pro forma revenue of US$685 million. Both Boards recommend their shareholders vote ‘FOR’ the transaction. Expected cost synergies of US$78 million will enhance operational efficiency, while the combined company aims for growth in domestic and international markets.

Tilray (NASDAQ: TLRY) has received approvals from New Zealand's Ministry of Health to launch its medical cannabis products nationwide. As a leading provider in Australia and New Zealand, Tilray aims to offer high-quality medical cannabis products, starting with its Purified CBD line. By Q2 2021, the company plans to expand its GMP-certified product range. Tilray collaborates with prominent research institutions to explore cannabis treatments for various health conditions. This expansion enhances patient access to medical cannabis in New Zealand.

Tilray, a global cannabis leader (Nasdaq: TLRY), announced its fiscal year 2020 and Q4 results, reporting a total revenue of $56.6 million, up 20.5% YoY, with cannabis revenue rising 46% to $41.2 million. The company achieved a net loss of $(3.0) million, significantly improved from $(219.8) million in Q4 2019. Adjusted EBITDA reached $2.2 million, marking a turnaround. Anticipating $100 million in synergies from its merger with Aphria, Tilray aims for enhanced market positioning. Cash reserves totaled $189.7 million, setting a solid foundation for future growth opportunities.

Tilray Inc. (TLRY), a leader in cannabis, will release its 2020 fiscal year and Q4 results on February 17, 2021, after market close. A conference call is scheduled for 5:00 p.m. ET, accessible via a U.S. toll-free number 877-407-0792, or internationally at 201-689-8263. The call will also be available through a live webcast on the Tilray website, which will later be archived for viewing.

Tilray Inc. (NASDAQ: TLRY) has partnered with Grow Pharma to import and distribute medical cannabis products in the UK. This agreement facilitates access for UK patients to GMP-certified medical cannabis solutions. Tilray plans to offer a range of products by March 2021, available through private practices or the NHS. According to CEO Brendan Kennedy, this partnership is a significant step in improving patient access in the UK, while Managing Director Sascha Mielcarek emphasizes the company's commitment to becoming a leading supplier as demand increases.

Tilray, a global leader in cannabis, announced its first export of GMP-certified medical cannabis from Portugal to Spain, in collaboration with Worldpharma Biotech. This shipment, approved by Spain's AEMPS, will support clinical trials for conditions such as Alzheimer's and Parkinson's. Tilray's pharmaceuticals-grade product is designed to meet stringent EU standards, enhancing patient access to reliable cannabis treatments. This milestone marks the 17th country receiving Tilray cannabis, showcasing its commitment to global medical cannabis standards.

Tilray, Inc. (NASDAQ: TLRY) has received market authorization from Infarmed in Portugal to offer its medical cannabis products, confirming compliance with strict quality and safety standards. This marks the first time a comprehensive quality dossier was required for market authorization in Europe. The approved products treat various conditions, including multiple sclerosis-related spasticity, severe seizure disorders, and chronic pain. With GMP certification, Tilray can manufacture and export medical cannabis products across the EU, catering to rising patient demand.

Tilray has been selected by the French National Agency for the Safety of Medicines and Health Products (ANSM) to supply GMP-certified medical cannabis products for experimentation in France. This initiative will last between 18 to 24 months, starting in Q1 2021, targeting patients with conditions like refractory neuropathic pain and drug-resistant epilepsy. Tilray's facility in Portugal will handle the production and export of these products. The announcement reflects Tilray's commitment to expanding operations in Europe and improving patient access to quality medical cannabis.

Tilray (Nasdaq: TLRY), a prominent player in the medical cannabis sector, has entered a co-promotion agreement with Hormosan, effective January 1, 2021. This collaboration aims to enhance marketing and sales for Tilray's full-spectrum cannabis extracts in Germany, leveraging Hormosan's expertise in pain therapy and neurology. Since launching its extracts in 2017, Tilray has expanded its offerings, which include various THC-CBD ratios, targeting chronic pain and sleep disorders. The partnership is expected to improve access for physicians and patients, ultimately benefiting patient care.